One Stop Solution For In-Depth Market Research Reports

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   NORTH AMERICA DIABETES DRUGS MARKET

NORTH AMERICA DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)


Product Code : MDHC00122047
Survey : Mordor Intelligence
Publish On : 12, August, 2022
Category : Healthcare and Pharmaceuticals
Study Area : North America (U.S. and Others), Europe (Germany, France, U.K. and Others), Asia-Pacific (Japan, China, India and Others), Rest of World (Brazil, Rest of Latin America, Middle East & Others)
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4950 / Question Form
5 User USD6750 / Question Form
Enterprise User USD9000 / Question Form
 - Novo Nordisk A/S
- Sanofi Aventis
- Eli Lilly
- Astra Zeneca
- Bristol Myers Squibb
- Boehringer Ingelheim
- Mylan
- Pfizer
- Janssen Pharmaceuticals
- Merck
- Astellas
- Teva
- Takeda
- Bayer
- Sun Pharma

[Report Description]

Key Highlights


  • North America dominates the diabetes drugs care market globally, and the US holds the highest market share in the North America region.

  • Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or does not produce insulin which is known as Type 1 diabetes, or because the body s cells do not respond appropriately to insulin which is called Type-2 diabetes mellitus, or both.

  • Approximately 10% of all diabetes cases are type-1, and about 90% of all cases of diabetes worldwide are of type-2.



Key Market Trends



Rising Prevalence of Diabetes




  • North America diabetes market size in 2019 was USD 33462.12 million with an expected CAGR of 6.19% during the forecast period 2018-2024.

  • The rising prevalence of diabetes in the United States is the most influencing factor driving the market for diabetes drugs in the region.

  • In 2017, 7.4% of the population of the United States, i.e., 24.18 million were diabetic. Statistics prove that one in ten individuals in the country has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).

  • With the increase in diabetes population, the need and demand for diabetes drugs are expected to increase in North America.

  • The other factors, such as better adoption than other therapies and government initiatives are driving the diabetes drugs market.

  • Canada also holds a significant share in the growth of the diabetic population with 3.4 million diabetic patients which comprise of 10.2% of the whole Canada population.



The US leads the Market in the North America Region




  • The US diabetes drugs market holds the largest market share in 2017 in North America region where insulins hold the highest share of USD 10368 million which attributes to 41% of the total US market in diabetic drugs followed by oral anti-diabetic drug with 35.6%.

  • Among the oral drugs, SGLT-2 and DPP-4 drugs market are highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market.

  • Factors like continuous updation of the label due to constant clinical trials will also lead to higher usage and growth in revenue.



Competitive Landscape




  • A large chunk of the diabetic population in the United States has been taking generic drugs during the past few years.

  • In 2017, per person, spending on diabetes drugs in the United States was more than any traditional medication. Half the prescribed drugs in this class were generics. Another cost concerning factor is seen in the Insulin market. There are no generic versions of the drug yet in the market though it is a very old invention.

  • While it is considered as a classical medication for diabetes, it is a costly affair for many people, which would eventually hinder the growth of the global diabetes drugs market.

  • The other factor, such as the regulatory framework and adverse reactions due to medications is also hindering the growth of the market.



Additional Benefits:



  • The market estimate (ME) sheet in Excel format

  • 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints

5 Porters Five Force Analysis
5.1 Threat of New Entrants
5.2 Bargaining Power of Buyers/Consumers
5.3 Bargaining Power of Suppliers
5.4 Threat of Substitute Products
5.5 Intensity of Competitive Rivalry

6 MARKET SEGMENTATION
6.1 By Product Type
6.1.1 Oral Drugs (Value and Volume, 2012-2024)
6.1.1.1 Biguanides
6.1.1.1.1 Metformin
6.1.1.2 Alpha-Glucosidase Inhibitors
6.1.1.2.1 Alpha-Glucosidase Inhibitors
6.1.1.3 Dopamine D2 receptor agonist
6.1.1.3.1 Bromocriptin
6.1.1.4 SGLT-2 inhibitors
6.1.1.4.1 Invokana (Canagliflozin)
6.1.1.4.2 Jardiance (Empagliflozin)
6.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
6.1.1.4.4 Suglat (Ipragliflozin)
6.1.1.5 DPP-4 inhibitors
6.1.1.5.1 Onglyza (Saxagliptin)
6.1.1.5.2 Tradjenta (Linagliptin)
6.1.1.5.3 Vipidia/Nesina(Alogliptin)
6.1.1.5.4 Galvus (Vildagliptin)
6.1.1.6 Sulfonylureas
6.1.1.6.1 Sulfonylureas
6.1.1.7 Meglitinides
6.1.1.7.1 Meglitinides
6.1.2 Insulins (Value and Volume, 2012-2024)
6.1.2.1 Basal or Long Acting Insulins
6.1.2.1.1 Lantus (Insulin Glargine)
6.1.2.1.2 Levemir (Insulin Detemir)
6.1.2.1.3 Toujeo (Insulin Glargine)
6.1.2.1.4 Tresiba (Insulin Degludec)
6.1.2.1.5 Basaglar (Insulin Glargine)
6.1.2.2 Bolus or Fast Acting Insulins
6.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
6.1.2.2.2 Humalog (Insulin Lispro)
6.1.2.2.3 Apidra (Insulin Glulisine)
6.1.2.3 Traditional Human Insulins
6.1.2.3.1 Novolin/Actrapid/Insulatard
6.1.2.3.2 Humulin
6.1.2.3.3 Insuman
6.1.2.4 Biosimilar Insulins
6.1.2.4.1 Insulin Glargine Biosimilars
6.1.2.4.2 Human Insulin Biosimilars
6.1.3 Combination drugs (Value and Volume, 2012-2024)
6.1.3.1 Insulin combinations
6.1.3.1.1 NovoMix (Biphasic Insulin Aspart)
6.1.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
6.1.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
6.1.3.2 Oral Combinations
6.1.3.2.1 Janumet (Sitagliptin and Metformin)
6.1.4 Non-Insulin Injectable drugs (Value and Volu, 2012-2024)
6.1.4.1 GLP-1 receptor agonists
6.1.4.1.1 Victoza (Liraglutide)
6.1.4.1.2 Byetta (Exenatide)
6.1.4.1.3 Bydureon (Exenatide)
6.1.4.1.4 Trulicity (Dulaglutide)
6.1.4.1.5 Lyxumia (Lixisenatide)
6.1.4.2 Amylin Analogue
6.1.4.2.1 Symlin (Pramlintide)
6.2 Geography
6.2.1 North America (Value and Volume, 2012-2024)
6.2.1.1 United States
6.2.1.1.1 By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)
6.2.1.1.2 By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)
6.2.1.2 Canada
6.2.1.2.1 By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)
6.2.1.2.2 By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)
6.2.1.3 Rest of North America
6.2.1.3.1 By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)
6.2.1.3.2 By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)

7 MARKET INDICATORS
7.1 Type-1 Diabetes population (2012-2024)
7.2 Type-2 Diabetes population (2012-2024)

8 COMPETITIVE LANDSCAPE
8.1 COMPANY PROFILES
8.1.1 Novo Nordisk A/S
8.1.2 Sanofi Aventis
8.1.3 Eli Lilly
8.1.4 Astra Zeneca
8.1.5 Bristol Myers Squibb
8.1.6 Boehringer Ingelheim
8.1.7 Mylan
8.1.8 Pfizer
8.1.9 Janssen Pharmaceuticals
8.1.10 Merck
8.1.11 Astellas
8.1.12 Teva
8.1.13 Takeda
8.1.14 Bayer
8.1.15 Sun Pharma
8.2 COMPANY SHARE ANALYSIS
8.2.1 Novo Nordisk A/S
8.2.2 Sanofi Aventis
8.2.3 Eli Lilly
8.2.4 Astra Zeneca
8.2.5 Janssen Pharmaceuticals
8.2.6 Merck
8.2.7 Astellas

9 MARKET OPPORTUNITIES AND FUTURE TRENDS

Shibuya data count

Shibuya Data Count is a reseller offering a variety of market research reports from different industries, provided by a global team of experienced research professionals who ensure the most reliable and up-to-date research analysis reports.

Recommended reports

+